BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas 2011;40:987-94. [PMID: 21697761 DOI: 10.1097/MPA.0b013e31821f66b4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Ruggeri RM, Altieri B, Grossrubatcher E, Minotta R, Tarsitano MG, Zamponi V, MIsidori A, Faggiano A, Colao AM; NIKE Group. Sex differences in carcinoid syndrome: A gap to be closed. Rev Endocr Metab Disord 2022. [PMID: 35292889 DOI: 10.1007/s11154-022-09719-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Kazaz SN, Öztop İ. Systemic Treatments and Related Side Effects in Neuroendocrine Tumors. Radionuclide Therapy 2022. [DOI: 10.1007/978-3-030-97220-2_10] [Reference Citation Analysis]
3 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
4 Pusceddu S, Rossi RE, Torchio M, Prinzi N, Niger M, Coppa J, Giacomelli L, Sacco R, Facciorusso A, Corti F, Raimondi A, Prisciandaro M, Colombo E, Beninato T, Del Vecchio M, Milione M, Di Bartolomeo M, de Braud F. Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. J Clin Med 2020;9:E2468. [PMID: 32752158 DOI: 10.3390/jcm9082468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
5 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
6 Fisher GA. Gastroenteropancreatic Neuroendocrine Tumors. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_16] [Reference Citation Analysis]
7 Lau SC, Abdel-Rahman O, Cheung WY. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Med Oncol 2018;35:123. [PMID: 30078166 DOI: 10.1007/s12032-018-1189-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Barrows SM, Cai B, Copley-Merriman C, Wright KR, Castro CV, Soufi-Mahjoubi R. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World J Meta-Anal 2018; 6(2): 9-20 [DOI: 10.13105/wjma.v6.i2.9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Kaltsas G, I. Alexandraki K, Grossman AB. Acute Endocrine and Metabolic Emergencies Related to Neuroendocrine Tumors. Endocrine and Metabolic Medical Emergencies 2018. [DOI: 10.1002/9781119374800.ch29] [Reference Citation Analysis]
10 Yau H, Kinaan M, Quinn SL, Moraitis AG. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. Biologics. 2017;11:115-122. [PMID: 29255345 DOI: 10.2147/btt.s108818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
11 Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomed Res Int 2017;2017:9856140. [PMID: 29349087 DOI: 10.1155/2017/9856140] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
12 Broder MS, Chang E, Reddy SR, Neary MP. Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors. Pancreas 2017;46:891-7. [PMID: 28697129 DOI: 10.1097/MPA.0000000000000872] [Reference Citation Analysis]
13 Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine. 2017;57:366-375. [PMID: 28726183 DOI: 10.1007/s12020-017-1360-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
14 Pokuri VK, Fong MK, Iyer R. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep 2016;18:7. [PMID: 26743514 DOI: 10.1007/s11912-015-0492-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
15 Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17:2191-2205. [PMID: 27635672 DOI: 10.1080/14656566.2016.1236916] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
16 Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 2016;3:175-89. [PMID: 27347369 DOI: 10.2217/ije-2015-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
17 Al-Efraij K, Aljama MA, Kennecke HF. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med 2015;4:864-70. [PMID: 25727756 DOI: 10.1002/cam4.435] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
18 Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955 [PMID: 25684964 DOI: 10.3748/wjg.v21.i6.1945] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
19 Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19:930-936. [PMID: 25096997 DOI: 10.1634/theoncologist.2014-0120] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 7.9] [Reference Citation Analysis]
20 Vinik AI, Vinik E, Diebold A, Woltering E. Measuring the Relationship of Quality of Life and Health Status: Including Tumor Burden, Symptoms, and Biochemical Measures in Patients with Neuroendocrine Tumors. Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract 2014. [DOI: 10.1007/978-2-8178-0430-9_14] [Reference Citation Analysis]
21 Chung-Delgado K, Revilla-Montag A, Guillén-Bravo S, Ríos-Díaz H, Alva-Muñoz JC. Refractory thrombocytopenia responds to octreotide treatment in a case of evans syndrome with gastric neuroendocrine tumor. Case Rep Hematol 2013;2013:391086. [PMID: 23984123 DOI: 10.1155/2013/391086] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Araujo PB, Cheng S, Mete O, Serra S, Morin E, Asa SL, Ezzat S. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS One 2013;8:e61538. [PMID: 23620762 DOI: 10.1371/journal.pone.0061538] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]